Cardiovascular : Closing Comments

Capital Markets Day - August 3, 2022

Closing Comments

Scott R. Ward

Chairman, President & Chief Executive Officer

Safe Harbor

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act.

For example, statements in this presentation regarding CSI's strategy, goals, growth, future financial measurements, product development and introductions, geographic expansion, reimbursement expectations, acquisition of products in development, distributed products, clinical trials, future investments and financing needs, and market opportunities, are forward-looking statements. These statements involve risks and uncertainties that could cause results differ materially from those projected, including, but not limited to, those described in CSI's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly and annual reports. CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this presentation. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, CSI's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this presentation. The forward-looking statements contained in this presentation are made only as of the date of this presentation, and CSI undertakes no obligation to update them to reflect subsequent events or circumstances.

Financial Disclaimers

Financial Information

This presentation includes calculations or figures that have been prepared internally and have not been reviewed or audited by CSI's independent registered accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences, which may be material.

Market Estimates

Unless noted otherwise, any references to market sizes, market share positions, and market growth rates are CSI internal estimates.

Non-GAAP Financial Measures

This presentation also refers to certain non-GAAP financial measures, such as Adjusted EBITDA. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for CSI's financial results prepared in accordance with GAAP.

Regulatory Disclaimers

Product		Availability
Diamondback 360® Coronary Orbital Atherectomy System		FDA-approved. Available for
		sale in the U.S.
Diamondback 360® Peripheral Orbital Atherectomy System		FDA-cleared. Available for
		sale in the U.S.
Diamondback 360® Peripheral Orbital Atherectomy System -		FDA-cleared. Available for
Exchangeable Series		sale in the U.S.
Stealth 360® Peripheral Orbital Atherectomy System		FDA-cleared. Available for
		sale in the U.S.
Peripheral Orbital Atherectomy System 2.00 Max Crown		FDA-cleared. Available under
(available with Diamondback 360®, Exchangeable Series, and		a Limited Market Release in
Stealth 360® Peripheral Orbital Atherectomy Systems)		the U.S.
ViperCath™ XC Peripheral Exchange Catheter		FDA-cleared. Available for
	sale in the U.S.
Zilient® Peripheral Guidewire		FDA-cleared. Available for
		sale in the U.S.
Jade® PTA Balloon Dilatation Catheter		FDA-cleared. Available for
		sale in the U.S.
Sapphire® II PRO Balloon Dilatation Catheter		FDA-cleared. Available for
		sale in the U.S.
Sapphire® NC 24 Coronary Dilatation Catheter		FDA-cleared. Available for
		sale in the U.S.
Sapphire® NC Plus Coronary Dilatation Catheter		FDA-cleared. Available for
		sale in the U.S.
Scoreflex® NC Scoring PTCA Catheter		FDA-approved. Available for
		sale in the U.S.
Shepherd™ Peripheral Guidewire		FDA-cleared. Available for
	sale in the U.S.

Product	Availability
Teleport® Microcatheter	FDA-cleared. Available for
	sale in the U.S.
ViperCross™ Support Catheter	FDA-cleared. Available for
sale in the U.S.
Diamondback 360 Precision™ Coronary Orbital	Product is in development.
Atherectomy System	Not available for sale.
Next Gen Orbital Atherectomy System	Product is in development.
(Coronary and Peripheral)	Not available for sale.
Coronary Orbital Atherectomy System Guidance Platform	Product is in development.
Not available for sale.
Coronary Orbital Atherectomy System Crown Extensions	Product is in development.
(1.0mm Piloting)	Not available for sale.
Coronary Antegrade/Retrograde Microcatheters	Product is in development.
Not available for sale.
Coronary Dual Access Catheter	Product is in development.
Not available for sale.
Coronary Guide Extension Catheter	Product is in development.
Not available for sale.
Everolimus Drug Coated Balloon (Coronary and Peripheral)	Product is in development.
Not available for sale.
Intravascular Lithotripsy (Coronary and Peripheral)	Product is in development.
Not available for sale.
Thrombectomy Clot Retriever	Product is in development.
Not available for sale.
Thrombectomy Aspiration Catheter	Product is in development.
Not available for sale.
Next Gen WIRION® Embolic Protection System	Product is in development.
	Not available for sale.
Percutaneous Ventricular Assist Device (pVAD)	Product is in development.
Not available for sale.

Key Milestones and Success Factors

Fiscal Year 23

• Leadership in Atherectomy
• Sequential momentum, improving commercial execution & competitiveness
• Organic growth & globalization
• Rapid growth in ISD sales
• New products: 2.0 Max, ScoreFlex and the CTO Toolkit
• Core competence in Quality, Manufacturing, R&D and Commercialization

Fiscal Year 24 - 25

• Grow and protect the global OAS franchise
• Sustain double-digit core business growth
• Continue to gain leverage with increased revenue per procedure and growth in ISD sales
• New products and platforms: WIRION EPD, Thrombectomy for DVT & PE, IVL for PAD
• Expand medical evidence with
  ECLIPSE
• Invest in Sales channel for pulmonary embolism and pipeline R&D programs

Fiscal Year 26 - 27

• A scaled, leading platform in complex cardiovascular medicine
• Sustain double-digit core business growth
• Global presence poised for future pipeline launches
• ISD sales reach $2,000 per procedure in coronary and $400 in peripheral
• New platform products: IVL for coronary, DCB for coronary and peripheral, mechanical circulatory support
• Sustained profitability with launch of platform products